Erythropoietin receptor contributes to melanoma cell survival in vivo

Oncogene

Volumn 31, Issue 13, 2012, Pages 1649-1660

  Kumar, S M ^a   Zhang, G ^b   Bastian, B C ^c   Arcasoy, M O ^d   Karande, P ^e   Pushparajan, A ^a   Acs, G ^f   Xu, X ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b WISTAR INSTITUTE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e RENSSELAER POLYTECHNIC INSTITUTE   (United States)

^f H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

erythropoietin; erythropoietin receptor; hypoxia; melanoma

Indexed keywords

CISPLATIN; ERYTHROPOIETIN RECEPTOR; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CANCER RECURRENCE; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENE DOSAGE; GENE LOCUS; GENE SILENCING; HYPOXIA; IN VITRO STUDY; IN VIVO STUDY; MELANOMA; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE PROGRESSION; DNA COPY NUMBER VARIATIONS; ERYTHROPOIETIN; GENE KNOCKDOWN TECHNIQUES; HUMANS; MELANOMA; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, ERYTHROPOIETIN; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TRANSCRIPTIONAL ACTIVATION;

EID: 84860420791     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.366     Document Type: Article

References (48)

1. Acs G, Acs P, Beckwith SM, Pitts RL, Clements E, Wong K et al. (2001). Erythropoietin and erythropoietin receptor expression in human cancer. Cancer Res 61: 3561-3565. (Pubitemid 32694960)
2. Acs G, Chen M, Xu X, Acs P, Verma A, Koch CJ. (2004a). Autocrine erythropoietin signaling inhibits hypoxia-induced apoptosis in human breast carcinoma cells. Cancer Lett 214: 243-251. (Pubitemid 39207986)
3. Acs G, Xu X, Chu C, Acs P, Verma A. (2004b). Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer 100: 2376-2386. (Pubitemid 38657885)
4. Arcasoy MO. (2008). Erythropoiesis-stimulating agent use in cancer: preclinical and clinical perspectives. Clin Cancer Res 14: 4685-4690.
5. Arcasoy MO, Amin K, Chou SC, Haroon ZA, Varia M, Raleigh JA. (2005). Erythropoietin and erythropoietin receptor expression in head and neck cancer: relationship to tumor hypoxia. Clin Cancer Res 11: 20-27. (Pubitemid 40075774)
6. Arcasoy MO, Amin K, Karayal AF, Chou SC, Raleigh JA, Varia MA et al. (2002). Functional significance of erythropoietin receptor expression in breast cancer. Lab Invest 82: 911-918. (Pubitemid 34761666)
7. Arcasoy MO, Jiang X, Haroon ZA. (2003). Expression of erythropoietin receptor splice variants in human cancer. Biochem Biophys Res Commun 307: 999-1007. (Pubitemid 36871672)
8. Belda-Iniesta C, Perona R, Carpeno JC, Cejas P, Casado E, Manguan-Garcia C et al. (2007). Human recombinant erythropoietin does not promote cancer growth in presence of functional receptors expressed in cancer cells. Cancer Biol Ther 6: 1600-1605. (Pubitemid 351590332)
9. Bennett CL, Silver SM, Djulbegovic B, Samaras AT, Blau CA, Gleason KJ et al. (2008). Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299: 914-924. (Pubitemid 351397066)
10. Blau CA. (2007). Erythropoietin in cancer: presumption of innocence? Stem Cells 25: 2094-2097.
11. Bohlius J, Schmidlin K, Brillant C, Schwarzer G, Trelle S, Seidenfeld J et al. (2009). Erythropoietin or darbepoetin for patients with cancer-meta-analysis based on individual patient data. Cochrane Database Syst Rev, CD007303.
12. Carlin S, Khan N, Ku T, Longo VA, Larson SM, Smith-Jones PM. (2010). Molecular targeting of carbonic anhydrase IX in mice with hypoxic HT29 colorectal tumor xenografts. PLoS One 5: e10857.
13. Constantinescu SN, Ghaffari S, Lodish HF. (1999). The erythropoietin receptor: structure, activation and intracellular signal transduction. Trends Endocrinol Metab 10: 18-23. (Pubitemid 29288706)
14. Curtin JA, Fridlyand J, Kageshita T, Patel HN, Busam KJ, Kutzner H et al. (2005). Distinct sets of genetic alterations in melanoma. N Engl J Med 353: 2135-2147. (Pubitemid 41653105)
15. Daniel RJ, Groves RW. (2002). Increased migration of murine keratinocytes under hypoxia is mediated by induction of urokinase plasminogen activator. J Invest Dermatol 119: 1304-1309. (Pubitemid 36005613)
16. Fu P, Jiang X, Arcasoy MO. (2009). Constitutively active erythropoietin receptor expression in breast cancer cells promotes cellular proliferation and migration through a MAP-kinase dependent pathway. Biochem Biophys Res Commun 379: 696-701.
17. Hardee ME, Cao Y, Fu P, Jiang X, Zhao Y, Rabbani ZN et al. (2007). Erythropoietin blockade inhibits the induction of tumor angiogenesis and progression. PLoS One 2: e549.
18. Henke M, Laszig R, Rube C, Schafer U, Haase KD, Schilcher B et al. (2003). Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 362: 1255-1260. (Pubitemid 37324251)
19. Jelkmann W, Bohlius J, Hallek M, Sytkowski AJ. (2008). The erythropoietin receptor in normal and cancer tissues. Crit Rev Oncol Hematol 67: 39-61.
20. Jeong JY, Hoxhaj G, Socha AL, Sytkowski AJ, Feldman L. (2009). An erythropoietin autocrine/paracrine axis modulates the growth and survival of human prostate cancer cells. Mol Cancer Res 7: 1150-1157.
21. Knabe W, Siren AL, Ehrenreich H, Kuhn HJ. (2005). Expression patterns of erythropoietin and its receptor in the developing spinal cord and dorsal root ganglia. Anat Embryol (Berl) 210: 209-219. (Pubitemid 41483259)
22. Koritzinsky M, Wouters BG. (2007). Hypoxia and regulation of messenger RNA translation. Methods Enzymol 435: 247-273.
23. Kumar SM, Acs G, Fang D, Herlyn M, Elder DE, Xu X. (2005). Functional erythropoietin autocrine loop in melanoma. Am J Pathol 166: 823-830. (Pubitemid 40315639)
24. Kumar SM, Yu H, Edwards R, Chen L, Kazianis S, Brafford P et al. (2007). Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma. Cancer Res 67: 3177-3184. (Pubitemid 46724855)
25. Lai SY, Childs EE, Xi S, Coppelli FM, Gooding WE, Wells A et al. (2005). Erythropoietin-mediated activation of JAK-STAT signaling contributes to cellular invasion in head and neck squamous cell carcinoma. Oncogene 24: 4442-4449. (Pubitemid 40961767)
26. LaMontagne KR, Butler J, Marshall DJ, Tullai J, Gechtman Z, Hall C et al. (2006). Recombinant epoetins do not stimulate tumor growth in erythropoietin receptor-positive breast carcinoma models. Mol Cancer Ther 5: 347-355.
27. Ley CD, Olsen MW, Lund EL, Kristjansen PE. (2004). Angiogenic synergy of bFGF and VEGF is antagonized by angiopoietin-2 in a modified in vivo Matrigel assay. Microvasc Res 68: 161-168. (Pubitemid 40288112)
28. Leyland-Jones B, Semiglazov V, Pawlicki M, Pienkowski T, Tjulandin S, Manikhas G et al. (2005). Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 23: 5960-5972.
29. Lin WM, Baker AC, Beroukhim R, Winckler W, Feng W, Marmion JM et al. (2008). Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 68: 664-673. (Pubitemid 351206741)
30. Mirmohammadsadegh A, Marini A, Gustrau A, Delia D, Nambiar S, Hassan M et al. (2010). Role of erythropoietin receptor expression in malignant melanoma. J Invest Dermatol 130: 201-210.
31. Mohyeldin A, Lu H, Dalgard C, Lai SY, Cohen N, Acs G et al. (2005). Erythropoietin signaling promotes invasiveness of human head and neck squamous cell carcinoma. Neoplasia 7: 537-543. (Pubitemid 40791872)
32. Noguchi CT, Wang L, Rogers HM, Teng R, Jia Y. (2008). Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev Mol Med 10: e36.
33. Okazaki T, Ebihara S, Asada M, Yamanda S, Niu K, Arai H. (2008). Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis. Neoplasia 10: 932-939.
34. Paragh G, Kumar SM, Rakosy Z, Choi SC, Xu X, Acs G. (2009). RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 human ovarian carcinoma cells. Am J Pathol 174: 1504-1514.
35. Pharr PN, Hankins D, Hofbauer A, Lodish HF, Longmore GD. (1993). Expression of a constitutively active erythropoietin receptor in primary hematopoietic progenitors abrogates erythropoietin dependence and enhances erythroid colony-forming unit, erythroid burst-forming unit, and granulocyte/macrophage progenitor growth. Proc Natl Acad Sci USA 90: 938-942. (Pubitemid 23053925)
36. Reynolds CP, Sun BC, DeClerck YA, Moats RA. (2005). Assessing growth and response to therapy in murine tumor models. Methods Mol Med 111: 335-350.
37. Seaman ME, Peirce SM, Kelly K. (2011). Targeting HIF-1 for cancer therapy. PLoS One 6: e20807.
38. Sinclair AM, Todd MD, Forsythe K, Knox SJ, Elliott S, Begley CG. (2007). Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer 110: 477-488. (Pubitemid 47106135)
39. Sytkowski AJ. (2007). Does erythropoietin have a dark side? Epo signaling and cancer cells. Sci STKE 2007: e38.
40. Tovari J, Gilly R, Raso E, Paku S, Bereczky B, Varga N et al. (2005). Recombinant human erythropoietin alpha targets intratumoral blood vessels, improving chemotherapy in human xenograft models. Cancer Res 65: 7186-7193. (Pubitemid 41161249)
41. Tovari J, Pirker R, Timar J, Ostoros G, Kovacs G, Dome B. (2008). Erythropoietin in cancer: an update. Curr Mol Med 8: 481-491.
42. Tsai PT, Ohab JJ, Kertesz N, Groszer M, Matter C, Gao J et al. (2006). A critical role of erythropoietin receptor in neurogenesis and post-stroke recovery. J Neurosci 26: 1269-1274. (Pubitemid 43237059)
43. Um M, Gross AW, Lodish HF. (2007). A 'classical' homodimeric erythropoietin receptor is essential for the antiapoptotic effects of erythropoietin on differentiated neuroblastoma SH-SY5Y and pheochromocytoma PC-12 cells. Cell Signal 19: 634-645. (Pubitemid 46107815)
44. Wouters BG, Koritzinsky M. (2008). Hypoxia signalling through mTOR and the unfolded protein response in cancer. Nat Rev Cancer 8: 851-864.
45. Wright GL, Hanlon P, Amin K, Steenbergen C, Murphy E, Arcasoy MO. (2004). Erythropoietin receptor expression in adult rat cardiomyocytes is associated with an acute cardioprotective effect for recombinant erythropoietin during ischemia-reperfusion injury. FASEB J 18: 1031-1033. (Pubitemid 39561515)
46. Wu H, Klingmuller U, Besmer P, Lodish HF. (1995). Interaction of the erythropoietin and stem-cell-factor receptors. Nature 377: 242-246.
47. Yates CM, Patel A, Oakley K, Helms A, Tuttle RM, Francis GL. (2006). Erythropoietin in thyroid cancer. J Endocrinol Invest 29: 320-329. (Pubitemid 43905322)
48. Yu T, Ye H, Chen Z, Ziober BL, Zhou X. (2008). Dimension reduction and mixed-effects model for microarray meta-analysis of cancer. Front Biosci 13: 2714-2720. (Pubitemid 351611604)